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Short Communication 
LONG-STANDING RAT KIDNEY GRAFT SURVIVAL BY A COMBINATION OF ORGAN PERFUSION 
WITH MHC CLASS 11 MONOCLONAL ANTIBODY AND IMMUNOSUPPRESSION WITH REDUCEO 
DOSES OF 15-DEOXYSPERGUALIN. 
M. Krzymanski, A. M. Waaga, K. Ulrichs and W. MUller-Ruchholtz 
Department of Nephrology, Medical Academy of Poznan, Poland, 
and Department of Immunology University of Kiel, D-2300 Kiel 1, FRG. 
To decrease the immunogenicity ?f 
anti-MHC class II (coded by the 
(MoAb 29Al, Dept. of Immunel. 
rat kidneys, grafts were perfused with an 
l-E subregi on) mouse monoe 1 ona 1 ant i body 
Kiel) as described previously (5). How 
effectively class lI-positive cells, which were mainly dendritic in 
appearance, were surface labelled by this procedure was checked by staining 
MoAb-perfused k i dney sect ions with peroxi dase-conjugated rabbi t ant i ··mouse 
antiglobulin and comparing them with in vitra MoAb-incubated sections. The 
results are presented in Table I. 
It was found that after 60 min. of perfusion/incubatian with MaAb almost 
all dendritic cel1s were label1ed. The labelling was superior to that after 
30 min. but not inferior to that after 120 min. Therefore 60 min. perfu-
si on/i neubation was chosen for graft pretreatment before transplantat; on, 
which was done in the rat inbred strain system DA (RTl a) to LEW (RTl 11. 
This procedure prelonged graft survival significantly though not satisfac-
torily from the biological point of view (9.6±O.8 versus 7.7:t.O.5 days in 
the control group, p<O.02). It was shown that the dendritic cells were not 
killed but only blocked. Several hours after transplantation the MoAb dis-
sociated fram these cells. Similar observations were made by Jablonski et 
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Table I: Extent of 1abelling of MHC class 11 surface-positive kidney cel1s 
with MoAb. 
Rat 
strain 
LEW 
LEW 
DA 
DA 
Primary No. of 
antibody (MoAb) kidneys 
incubation 
in vitro 
perfusion 
in vitra 
perfusion 
studied 
2 
2 
2 
2 
Labelled interstitial 
dendritic cells/mm2 
n x + SO 
38 38 1. 21 
22 50 + 18 
39 78 ± 24 
17 100 ±. 32 
Immunoperoxidase 
staining intensity 
4 + 
3 + 
4 + 
3 + 
n total number of investigated sectors (mm2) per kidney; x arithmetic mean 
value; SO standard deviation. 
Table 11: Duration of labelling of MHC class 11 surface-positive kidney 
cells with MoAb. 
Hours after 
grafting 
4 
8 
24 
48 
Cells labelled with MoAb 
100% dendritic cel1s 
30-40% dendritic cells 
single cells positive 
all cells negative 
Staining 
i ntensity 
+++ 
++ 
++ 
al. (4), though the time after which MaAb dissociated fram dendritic cells 
was shorter than in aur study. The results are presented in Table 11. 
Furthermore, it was shown that during the first day after transplantation 
donor cells migrated into the recipient's spleen and mesenteric 1ymph 
nades. The number of these cells located within the spleen's lymphoid 
follicles was smaller when the transplanted organ was perfused with MoAb 
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Table 111: Kidney allagraft survival time after 15-005 treatment. 
---- -- -- --- - - ------- - - -- --- - ------ - - - ---- - --- -- - - --- -- --- ---- - -
Dose of 
15-00S 
Control 
group 
0.05 
mg/kg 
0.3 
mg/kg 
0.5 
mg/kg 
- -- -- - -- --------------------- ---- ----- -- - ----- -- - --- - - --- -- - - - -
Graft 
survival 
days 
n 
p 
7.7+0.5 8.3+0.5 
10 3 
16 .5+0.5 > 150 >150 
3 3 3 
p<.O.Ol 
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(1.6~O.6 versus 3.3~1.7 pet' lymphoid follic1e sect'ion in the contral 
group). On the second day after transplantation infiltration of the graft 
by host class lI-positive ce11s began. Thi !; was de1ayed by one day when the 
graft was perfused with MoAb. Taken together, these resu1ts indicate that 
perfusi on of the graft with MoAb reduced the number of donar ce 11 s, 
temporarily inhibited their function and dE~layed the migration of recipient 
cells into the graft. 
1I 
Dur findings suggest that a bidirectional sys,tem of cell migration between 
the graft and the host ex-j sts whi ch may provi de both "centra 1 " and 
peripheral" al10antigen presentation. In "central" sensitization donor 
ce 11 s part i ci pate by mi grat ion i nto the reci p'j ent I s spleen. The phenomenon 
of dendritic cell migration was recent1y reviewed by Austyn and Larsen (2). 
In "peripheral" sensitization host cells participate by penetration into 
the graft, and donor cel1s by 10cal antigen presentation. The role of host 
ce 11 s in a 11 oanti gen presentat i on has been studi ed and confi rmed by 
Ishikura at a1. (3), and Sherwood et a1. (7). Ruers at al. (6) concluded 
from their studü~s that the local events of allograft sensitization playa 
crucial role in the rejection response. 
Taking into consideration that graft rejection may be induced in these two 
ways we found it reasonable to combine MoAb perfusion of rat kidney with a 
low dose of the new i mmunosuppres si ve agent 1 !:;-deoxyspergua 1 in (15-00S) (1) 
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which ;s known to interfere with antigen presentation. To determine the 
minimum effective dose of 15-00S, doses of 0.05, 0.2, 0.3 and 0.5 mg/kg 
were gi ven i ntraperi tonea 11y for 14 days to LEW rats recel Vl ng DA ki dney 
grafts. Graft survi val in rats treated with vari ous doses of 15-00S i s 
presented in Tab1e Ir1. 
On the basis of these resu1ts a dose of 0.2 mg/kg was se1ected for further 
studi es. I n LEW rats recei vi ng MoAb-perfused ki dney grafts, mean graft 
surviva1 was 146,:!:.16 days (n=3). These data suggest that the reduction of 
graft immunogenicity achieved by perfusion with MoAb became biologically 
relevant only in combination with a low dose of 15-00S. This low-dose, 
short-term treatment initiates long-standing surviva1 of an MHC fu11y 
a110geneic organ graft. 
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